Clinical trials of CD22-specific CAR T cells to treat r/r B-ALL patients, many of who have had a prior CD19-targeted therapy, have resulted in complete responses in 57% [6] to 70% [7] of patients. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.